Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell CarcinomaMatthew S. Davids, Boon Cher Goh, Jeffrey P. Hodge et al.|Journal of Clinical Oncology|2009Cited by 81
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Ivana Rizzuto et al.|Journal of Clinical Oncology|2015Cited by 7